MV-130 is under clinical development by Inmunotek and currently in Phase II for Lower Respiratory Tract Infections.
212Pb-DOTAM-GRPR1 by Orano Med for Cervical Cancer: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug